Caisson Biotech

Caisson Biotech is a biopharmaceutical company that developed the HEPtune platform, a proprietary drug delivery technology based on heparosan, a naturally occurring polysaccharide. The technology is designed to enhance the therapeutic profile of biologics by increasing plasma half-life and reducing immunogenicity, serving as a biodegradable alternative to PEGylation. The company's primary focus was on metabolic diseases and hematology, leading to a significant partnership and eventual acquisition by Novo Nordisk. By conjugating heparosan to proteins and peptides, Caisson aimed to create bio-better therapeutics with improved dosing schedules and safety. The platform's versatility allows for application across various modalities, including enzymes and antibodies. Following its acquisition, the technology has been integrated into Novo Nordisk's internal development programs for diabetes and other chronic conditions.